Frovatriptan Succinate

Frovatriptan Succinate (CAS No.: 158930-09-7) is a synthetic small molecule triptan and the succinate salt form of frovatriptan, primarily categorized as a serotonergic receptor pharmacology tool for neurovascular and migraine related mechanism studies in biomedical research and early drug discovery workflows, with a functional profile characterized by potent and selective agonism at 5 HT1B and 5 HT1D receptors and substantially lower activity at other serotonin receptor subtypes such as 5 HT1A, 5 HT1F, and 5 HT7 as well as markedly weaker interaction with non serotonergic receptor families including dopamine, histamine H1, and alpha1 adrenergic receptors; mechanistically, it is used to probe serotonin dependent G protein coupled receptor signaling relevant to modulation of cyclic AMP linked pathways, neuropeptide release dynamics, and vascular smooth muscle response biology in experimental systems, and available pharmacology summaries indicate activity commonly discussed in the nanomolar to low micromolar range depending on assay format, receptor context, and endpoint definition; in practical research settings, this compound is applied as a reference or comparator agent in receptor selectivity profiling, pathway deconvolution studies, cell based functional assays, ex vivo tissue response experiments, and in vivo headache related or neurovascular translational models, while the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.